Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes

Sung Chao Chu, Tso Fu Wang, Chi Cheng Li, Ruey Ho Kao, Dian Kun Li, Yu Chieh Su, Denise A. Wells, Michael R. Loken

研究成果: 雜誌貢獻文章

43 引文 (Scopus)

摘要

The aim of this study is to validate the clinical utility of the flow cytometric scoring system (FCSS), quantifying phenotypic aberrancies in the myelomonocytic lineages, in the diagnosis and prognosis for conventionally treated myelodysplastic syndromes (MDS) patients. The bone marrow samples from 56 consecutive newly diagnosed MDS patients were characterized by the FCSS and compared with findings in 27 non-MDS cytopenic patients. The FCSS scores were significantly higher in patients with MDS than those in the non-MDS control. A flow score of 2 or more allowed for a specificity of 100% with 75% sensitivity in distinguishing these two groups. The FCSS scores correlated directly with validated prognostic systems including WHO classification, International Prognostic Scoring System (IPSS), WHO-adjusted prognostic scoring system (WPSS) and transfusion dependency. The median survival of conventionally treated MDS patients was directly related to FCSS group; severe: 6. months; moderate: 19. months and normal/mild: not reached. The multivariate analyses suggested the FCSS risk categories were an independent prognostic factor after adjustment for sex, age (above or below 70. years), IPSS or WPSS risk categories. These results confirm that quantifying aberrancies in the myelomonocytic lineage by FCSS is useful in MDS diagnosis and extends the prognostic utility for conventionally treated/untreated patients, especially among patients classified within the refractory cytopenia with multilineage dysplasia (RCMD) subgroup.
原文英語
頁(從 - 到)868-873
頁數6
期刊Leukemia Research
35
發行號7
DOIs
出版狀態已發佈 - 七月 1 2011
對外發佈Yes

指紋

Myelodysplastic Syndromes
Multivariate Analysis
Bone Marrow
Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

引用此文

Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. / Chu, Sung Chao; Wang, Tso Fu; Li, Chi Cheng; Kao, Ruey Ho; Li, Dian Kun; Su, Yu Chieh; Wells, Denise A.; Loken, Michael R.

於: Leukemia Research, 卷 35, 編號 7, 01.07.2011, p. 868-873.

研究成果: 雜誌貢獻文章

Chu, Sung Chao ; Wang, Tso Fu ; Li, Chi Cheng ; Kao, Ruey Ho ; Li, Dian Kun ; Su, Yu Chieh ; Wells, Denise A. ; Loken, Michael R. / Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. 於: Leukemia Research. 2011 ; 卷 35, 編號 7. 頁 868-873.
@article{54612932111d43a5af6f46455ec780e1,
title = "Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes",
abstract = "The aim of this study is to validate the clinical utility of the flow cytometric scoring system (FCSS), quantifying phenotypic aberrancies in the myelomonocytic lineages, in the diagnosis and prognosis for conventionally treated myelodysplastic syndromes (MDS) patients. The bone marrow samples from 56 consecutive newly diagnosed MDS patients were characterized by the FCSS and compared with findings in 27 non-MDS cytopenic patients. The FCSS scores were significantly higher in patients with MDS than those in the non-MDS control. A flow score of 2 or more allowed for a specificity of 100{\%} with 75{\%} sensitivity in distinguishing these two groups. The FCSS scores correlated directly with validated prognostic systems including WHO classification, International Prognostic Scoring System (IPSS), WHO-adjusted prognostic scoring system (WPSS) and transfusion dependency. The median survival of conventionally treated MDS patients was directly related to FCSS group; severe: 6. months; moderate: 19. months and normal/mild: not reached. The multivariate analyses suggested the FCSS risk categories were an independent prognostic factor after adjustment for sex, age (above or below 70. years), IPSS or WPSS risk categories. These results confirm that quantifying aberrancies in the myelomonocytic lineage by FCSS is useful in MDS diagnosis and extends the prognostic utility for conventionally treated/untreated patients, especially among patients classified within the refractory cytopenia with multilineage dysplasia (RCMD) subgroup.",
keywords = "Diagnosis, Flow cytometry, Myelodysplastic syndromes, Prognosis",
author = "Chu, {Sung Chao} and Wang, {Tso Fu} and Li, {Chi Cheng} and Kao, {Ruey Ho} and Li, {Dian Kun} and Su, {Yu Chieh} and Wells, {Denise A.} and Loken, {Michael R.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.leukres.2011.02.016",
language = "English",
volume = "35",
pages = "868--873",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes

AU - Chu, Sung Chao

AU - Wang, Tso Fu

AU - Li, Chi Cheng

AU - Kao, Ruey Ho

AU - Li, Dian Kun

AU - Su, Yu Chieh

AU - Wells, Denise A.

AU - Loken, Michael R.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - The aim of this study is to validate the clinical utility of the flow cytometric scoring system (FCSS), quantifying phenotypic aberrancies in the myelomonocytic lineages, in the diagnosis and prognosis for conventionally treated myelodysplastic syndromes (MDS) patients. The bone marrow samples from 56 consecutive newly diagnosed MDS patients were characterized by the FCSS and compared with findings in 27 non-MDS cytopenic patients. The FCSS scores were significantly higher in patients with MDS than those in the non-MDS control. A flow score of 2 or more allowed for a specificity of 100% with 75% sensitivity in distinguishing these two groups. The FCSS scores correlated directly with validated prognostic systems including WHO classification, International Prognostic Scoring System (IPSS), WHO-adjusted prognostic scoring system (WPSS) and transfusion dependency. The median survival of conventionally treated MDS patients was directly related to FCSS group; severe: 6. months; moderate: 19. months and normal/mild: not reached. The multivariate analyses suggested the FCSS risk categories were an independent prognostic factor after adjustment for sex, age (above or below 70. years), IPSS or WPSS risk categories. These results confirm that quantifying aberrancies in the myelomonocytic lineage by FCSS is useful in MDS diagnosis and extends the prognostic utility for conventionally treated/untreated patients, especially among patients classified within the refractory cytopenia with multilineage dysplasia (RCMD) subgroup.

AB - The aim of this study is to validate the clinical utility of the flow cytometric scoring system (FCSS), quantifying phenotypic aberrancies in the myelomonocytic lineages, in the diagnosis and prognosis for conventionally treated myelodysplastic syndromes (MDS) patients. The bone marrow samples from 56 consecutive newly diagnosed MDS patients were characterized by the FCSS and compared with findings in 27 non-MDS cytopenic patients. The FCSS scores were significantly higher in patients with MDS than those in the non-MDS control. A flow score of 2 or more allowed for a specificity of 100% with 75% sensitivity in distinguishing these two groups. The FCSS scores correlated directly with validated prognostic systems including WHO classification, International Prognostic Scoring System (IPSS), WHO-adjusted prognostic scoring system (WPSS) and transfusion dependency. The median survival of conventionally treated MDS patients was directly related to FCSS group; severe: 6. months; moderate: 19. months and normal/mild: not reached. The multivariate analyses suggested the FCSS risk categories were an independent prognostic factor after adjustment for sex, age (above or below 70. years), IPSS or WPSS risk categories. These results confirm that quantifying aberrancies in the myelomonocytic lineage by FCSS is useful in MDS diagnosis and extends the prognostic utility for conventionally treated/untreated patients, especially among patients classified within the refractory cytopenia with multilineage dysplasia (RCMD) subgroup.

KW - Diagnosis

KW - Flow cytometry

KW - Myelodysplastic syndromes

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=79958763369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958763369&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.02.016

DO - 10.1016/j.leukres.2011.02.016

M3 - Article

VL - 35

SP - 868

EP - 873

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -